» Articles » PMID: 19058322

Function of the Hemochromatosis Protein HFE: Lessons from Animal Models

Overview
Specialty Gastroenterology
Date 2008 Dec 6
PMID 19058322
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Hereditary hemochromatosis (HH) is caused by chronic hyperabsorption of dietary iron. Progressive accumulation of excess iron within tissue parenchymal cells may lead to severe organ damage. The most prevalent type of HH is linked to mutations in the HFE gene, encoding an atypical major histocompatibility complex class I molecule. Shortly after its discovery in 1996, the hemochromatosis protein HFE was shown to physically interact with transferrin receptor 1 (TfR1) and impair the uptake of transferrin-bound iron in cells. However, these findings provided no clue why HFE mutations associate with systemic iron overload. It was later established that all forms of HH result from misregulation of hepcidin expression. This liver-derived circulating peptide hormone controls iron efflux from duodenal enterocytes and reticuloendothelial macrophages by promoting the degradation of the iron exporter ferroportin. Recent studies with animal models of HH uncover a crucial role of HFE as a hepatocyte iron sensor and upstream regulator of hepcidin. Thus, hepatocyte HFE is indispensable for signaling to hepcidin, presumably as a constituent of a larger iron-sensing complex. A working model postulates that the signaling activity of HFE is silenced when the protein is bound to TfR1. An increase in the iron saturation of plasma transferrin leads to displacement of TfR1 from HFE and assembly of the putative iron-sensing complex. In this way, iron uptake by the hepatocyte is translated into upregulation of hepcidin, reinforcing the concept that the liver is the major regulatory site for systemic iron homeostasis, and not merely an iron storage depot.

Citing Articles

The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.

Kontoghiorghes G Int J Mol Sci. 2024; 25(9).

PMID: 38731873 PMC: 11083551. DOI: 10.3390/ijms25094654.


Iron, Copper, and Zinc Homeostasis: Physiology, Physiopathology, and Nanomediated Applications.

Szabo R, Bodolea C, Mocan T Nanomaterials (Basel). 2021; 11(11).

PMID: 34835722 PMC: 8620808. DOI: 10.3390/nano11112958.


Evidence That HFE H63D Variant Is a Potential Disease Modifier in Cluster Headache.

Papasavva M, Vikelis M, Katsarou M, Siokas V, Dermitzakis E, Papademetriou C J Mol Neurosci. 2021; 72(2):393-400.

PMID: 34570359 PMC: 8840935. DOI: 10.1007/s12031-021-01913-8.


New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.

Kontoghiorghes G, Kolnagou A, Demetriou T, Neocleous M, Kontoghiorghe C Int J Mol Sci. 2021; 22(11).

PMID: 34074010 PMC: 8197347. DOI: 10.3390/ijms22115546.


Higher iron stores and the HFE 187C>G variant delay onset of peripheral neuropathy during combination antiretroviral therapy.

Kallianpur A, Wen W, Erwin A, Clifford D, Hulgan T, Robbins G PLoS One. 2020; 15(10):e0239758.

PMID: 33057367 PMC: 7561201. DOI: 10.1371/journal.pone.0239758.


References
1.
Courselaud B, Pigeon C, Inoue Y, Inoue J, Gonzalez F, Leroyer P . C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem. 2002; 277(43):41163-70. DOI: 10.1074/jbc.M202653200. View

2.
Feder J, Penny D, Irrinki A, Lee V, Lebron J, Watson N . The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A. 1998; 95(4):1472-7. PMC: 19050. DOI: 10.1073/pnas.95.4.1472. View

3.
Swinkels D, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna E . Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS One. 2008; 3(7):e2706. PMC: 2442656. DOI: 10.1371/journal.pone.0002706. View

4.
Wigg A, Harley H, Casey G . Heterozygous recipient and donor HFE mutations associated with a hereditary haemochromatosis phenotype after liver transplantation. Gut. 2003; 52(3):433-5. PMC: 1773567. DOI: 10.1136/gut.52.3.433. View

5.
Ponka P, Beaumont C, Richardson D . Function and regulation of transferrin and ferritin. Semin Hematol. 1998; 35(1):35-54. View